QT-prolonging class I drug, disopyramide, does not aggravate but suppresses adrenaline-induced arrhythmias. Comparison with cibenzoline and pilsicainide

European Journal of Pharmacology

Volumn 400, Issue 2-3, 2000, Pages 263-269

  Miyamoto, Shigeki ^a   Zhu, Bing Mei ^a   Teramatsu, Tsuyoshi ^a   Aye, Nu Nu ^a   Hashimoto, Keitaro ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Adrenaline; Cibenzoline; Disopyramide; Dog; Pilsicainide; QTc

Indexed keywords

ADRENALIN; ANTIARRHYTHMIC AGENT; CIBENZOLINE; DISOPYRAMIDE; PILSICAINIDE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART RATE; MALE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; BLOOD PRESSURE; DISOPYRAMIDE; DOGS; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; EPINEPHRINE; FEMALE; HEART RATE; IMIDAZOLES; LIDOCAINE; MALE;

EID: 0034698340     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00418-0     Document Type: Article

References (22)

1. Borggrefe M., Haverkamp W., Shenasa M., Hindricks G., Breithardt G. How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach. J. Cardiovasc. Pharmacol. 20(Suppl. 2):1992;S32-S40.
2. Chen B.H., Taylor E.H., Pappas A.A. Total and free disopyramide by fluorescence polarization immunoassay and relationship between free fraction and alpha-1 acid glycoprotein. Clin. Chim. Acta. 163:1987;75-80.
3. Haruno A., Hashimoto K. Antiarrhythmic effects of bisaramil in canine models of ventricular arrhythmia. Eur. J. Pharmacol. 233:1993;1-6.
4. Hashimoto K., Hashimoto K. The mechanism of sensitization of the ventricle to epinephrine by halothane. Am. Heart J. 83:1972;652-658.
5. Hashimoto K., Sato H., Shibuya T., Imai S. Canine-effective plasma concentrations of antiarrhythmic drugs on the two-stage coronary ligation arrhythmia. J. Pharmacol. Exp. Ther. 223:1982;801-810.
6. Hashimoto K., Ishii M., Komori S., Mitsuhashi H. Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165. Heart Vessels. 1:1985;29-35.
7. Hashimoto K., Akiyama K., Mitsuhashi H. Antiarrhythmic plasma concentration of cibenzoline on canine ventricular arrhythmias. J. Cardiovasc. Pharmacol. 9:1987;148-153.
8. Hashimoto K., Haruno A., Matsuzaki T., Sugiyama A., Akiyama K. Effects of antiarrhythmic drugs on canine ventricular arrhythmia models: which electrophysiological characteristics of drugs are related to their effectiveness? Cardiovasc. Drugs Ther. 5:1991;805-818.
9. Hiraoka M., Kuga K., Kawano S., Sunami A., Fan Z. New observations on the mechanisms of antiarrhythmic actions of disopyramide on cardiac membranes. Am. J. Cardiol. 64:1989;15J-19J.
10. Hondeghem L.M., Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation. 81:1990;686-690.
11. Ino T., Atarashi H., Kuruma A., Onodera T., Saitoh H., Hayakawa H. Electrophysiologic and hemodynamic effects of a single oral dose of pilsicainide hydrochloride, a new class 1c antiarrhythmic agent. J. Cardiovasc. Pharmacol. 31:1998;157-164.
12. Inomata N., Ishihara T., Akaike N. SUN 1165: a new antiarrhythmic Na current blocker in ventricular myocytes of guinea-pig. Comp. Biochem. Physiol. C. 87:1987;237-243.
13. Matsubara I., Hashimoto K., Katano Y., Tsukada T., Matsuda H., Nabata H., Imai S. Antiarrhythmic effects of dl-l-(tert.butylamino)-3-[(2-propinyloxy)phenoxy]-2-propanol hydrochloride (Ko 1400-Cl), a new adrenergic β-blocking agent. Folia Pharmacol. Jpn. 72:1976;557-571.
14. 2+ channel blocker in models of ventricular arrhythmia in dogs. Eur. J. Pharmacol. 231:1993;363-370.
15. Sato T., Wu B., Kiyosue T., Arita M. Effects of cibenzoline, a new class Ia antiarrhythmic drug, on various membrane ionic currents and action potentials of guinea-pig ventricular cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 350:1994;167-173.
16. Shibuya T., Hashimoto K., Imai S. Effective plasma concentrations of antiarrhythmic drugs against sustained halothane-adrenaline arrhythmia in dogs. J. Cardiovasc. Pharmacol. 5:1983;538-545.
17. Spray D.C., Burt J.M. Structure-activity relations of the cardiac gap junction channel. Am. J. Physiol. 258:1990;C195-C205.
18. Virag L., Varro A., Papp J.G. Effect of disopyramide on potassium currents in rabbit ventricular myocytes. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1998;268-275.
19. Wit A.L., Rosen M.R. Afterdepolarizations and triggered activity: distinction from automaticity as an arrhythmogenic mechanism. Fozzard H.A., Haber E., Jennings R.B., Katz A.M., Morgan H.E. The Heart and Cardiovascular System. 2nd edn. 1992;2113-2163 Raven Press, New York.
20. Wu B., Sato T., Kiyosue T., Arita M. Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs. Cardiovasc. Res. 26:1992;1095-1101.
21. Xue Y.X., Yamada C., Aye N.N., Hashimoto K. MS-551 and KCB328, two class III drugs aggravated adrenaline-induced arrhythmias. Br. J. Pharmacol. 124:1998;1712-1718.
22. V(s) blocker, on canine ventricular arrhythmia models. Eur. J. Pharmacol. 376:1999;27-35.